ARCT:NASDAQ
Arcturus Therapeutics Holdings Inc
$16.43
arrow_downward
-2.95%(-0.50) 1D
Sep 18, 12:03:54 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ARCT...
Open
$16.68
High
$17.75
Low
$16.30
Mkt. cap
466.99M
Avg. vol.
1.29M
Volume
274.12K
52-wk high
$24.14
52-wk low
$5.50
EPS
-$3.31
Beta
2.48
Shares outstanding
28.42M
No. of employees
109
Open
$16.68
High
$17.75
Low
$16.30
Mkt. cap
466.99M
Avg. vol.
1.29M
Volume
274.12K
52-wk high
$24.14
52-wk low
$5.50
EPS
-$3.31
Beta
2.48
Shares outstanding
28.42M
No. of employees
109
News stories
From web sources and news partners
Yahoo Finance
·
3 hours ago
Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform
MEXC
·
3 hours ago
ArcTools Price Today: Live ARCT to USD Price Chart & Market Data
CarePlus VietNam
·
1 month ago
Arcturus Therapeutics (ARCT) Surges 5.92% to $8.05, Approaches Key Resistance at $8.45 - Sell Signal Alerts
Profile
Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA, messenger RNA, gene editing RNA, DNA, antisense oligonucleotides, and microRNA.
The company develops RNA therapeutics for the treatment of rare diseases such as ornithine transcarbamylase deficiency, and respiratory diseases such as cystic fibrosis. Vaccine medicines include a vaccine candidate for COVID-19 and an influenza vaccine in the preclinical development phase. The vaccine for COVID-19 was authorised in Japan in 2023 and the European Union in 2025. Wikipedia
About Arcturus Therapeutics Holdings Inc